A Randomized Controlled Trial of Intramuscular Gonadotropin-Releasing Hormone (GnRH)-analogue Stimulation Test Compared to Subcutaneous Injection to Diagnose in Girls with Central Precocious Puberty

Status

Unknown

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240719003

Enrollment

Registered

2024-07-19

Start date

2024-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

maximum LH level(tmax) for the diagnosis of CPP girls after GnRH-analogue stimulation test Central precocious puberty, diagnosis, Intramuscular, GnRH-analogue stimulation test

Interventions

The testing procedure for both groups follows the same sequence. When the patient arrives, begin by phlebotomy to intravenous line placement and collecting a baseline blood sample to measure LH, FSH,

Experimental Drug,Active Comparator Drug

Intramuscular (IM) GnRH-analogue stimulation test group,Subcutaneous (SC) GnRH-analogue stimulation test group

Eligibility

Sex/Gender

Female

Age

1 Years to 9 Years

Inclusion criteria

Inclusion criteria: Girls who presented with breast developed before 8 years at KCMH between the years 2024 and 2025 will be recruited.

Exclusion criteria

Exclusion criteria: Exogenous hormonal use, Congenital adrenal hyperplasia, Peripheral precocious puberty (Adrenal tumor, Ovarian tumor, or cyst, etc.)

Design outcomes

Primary

Measure	Time frame
the time to the maximum LH level (tmax) at maximum LH level Electrochemiluminescence immunoassay (ECLIA)	—

Countries

Thailand

Contacts

Public ContactWorapimon Lerdrassameethad

Faculty of Pediatrics, Chulalongkorn University

bammy_star@hotmail.com66654978519

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026